The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Prostate Cancer MORE >>

Susan Halabi, PhD, discusses an analysis that found that the risk of death from metastatic castration-resistant prostate cancer was nearly 20% lower in African-American men than in Caucasian men.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.